Gut microbial pathway identified as target for improved heart disease treatment

Researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The study found phenylacetylglutamine (PAG), produced by gut bacteria as a waste product, then absorbed and formed in the liver, interacts with previously undiscovered locations on beta-2 adrenergic receptors on heart cells once it enters the circulation.